Sana Biotechnology Inc. (NASDAQ:SANA) shares traded 14.85% higher at $3.79 on Wall Street last session.
In accordance with the data, 4 analysts cover Sana Biotechnology Inc. (NASDAQ:SANA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $5.00, we find $9.50. Given the previous closing price of $3.30, this indicates a potential upside of 187.88 percent. SANA stock price is now -20.13% away from the 50-day moving average and -39.43% away from the 200-day moving average. The market capitalization of the company currently stands at $761.26M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 2 analysts and a buy by 2. Brokers who have rated the stock have averaged $9.75 as their price target over the next twelve months.
With the price target of $40, Morgan Stanley recently initiated with Overweight rating for Sana Biotechnology Inc. (NASDAQ: SANA). On March 01, 2021, JP Morgan recently initiated its ‘Neutral’ rating on the stock quoting a target price of $35, while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, Yang Patrick Y, Director bought 28,000 shares of the company’s stock on Mar 21. The stock was bought for $204,400 at an average price of $7.30. Upon completion of the transaction, the Director now directly owns 174,250 shares in the company, valued at $0.66 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 18, EVP & General Counsel MacDonald James J. sold 333 shares of the business’s stock. A total of $2,091 was realized by selling the stock at an average price of $6.28. This leaves the insider owning 429,417 shares of the company worth $1.63 million. Insiders disposed of 333 shares of company stock worth roughly $1262.07 over the past 1 year. A total of 3.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SANA stock. A new stake in Sana Biotechnology Inc. shares was purchased by ALLY BRIDGE GROUP (NY) LLC during the first quarter worth $2,787,000. BNP PARIBAS ARBITRAGE, SNC invested $856,000 in shares of SANA during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in Sana Biotechnology Inc. valued at approximately $412,000. TREXQUANT INVESTMENT LP acquired a new stake in SANA for approximately $362,000. HRT FINANCIAL LP purchased a new stake in SANA valued at around $258,000 in the second quarter. In total, there are 187 active investors with 91.20% ownership of the company’s stock.
Sana Biotechnology Inc. (NASDAQ: SANA) opened at $3.3000 on Thursday. During the past 12 months, Sana Biotechnology Inc. has had a low of $3.15 and a high of $16.28. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.40, and a quick ratio of 4.40. The fifty day moving average price for SANA is $4.7452 and a two-hundred day moving average price translates $6.2571 for the stock.
The latest earnings results from Sana Biotechnology Inc. (NASDAQ: SANA) was released for Jun, 2022.
Sana Biotechnology Inc.(SANA) Company Profile
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington’s disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
